BRPI0917224A2 - formas cristalinas de um derivado de piridina - Google Patents
formas cristalinas de um derivado de piridinaInfo
- Publication number
- BRPI0917224A2 BRPI0917224A2 BRPI0917224A BRPI0917224A BRPI0917224A2 BR PI0917224 A2 BRPI0917224 A2 BR PI0917224A2 BR PI0917224 A BRPI0917224 A BR PI0917224A BR PI0917224 A BRPI0917224 A BR PI0917224A BR PI0917224 A2 BRPI0917224 A2 BR PI0917224A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline forms
- pyridine derivative
- pyridine
- derivative
- crystalline
- Prior art date
Links
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0814340.6A GB0814340D0 (en) | 2008-08-05 | 2008-08-05 | Anhydrous crystol form fo a pyridine derivative |
| PCT/EP2009/060089 WO2010015626A1 (en) | 2008-08-05 | 2009-08-04 | Crystalline forms of a pyridine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0917224A2 true BRPI0917224A2 (pt) | 2015-11-24 |
Family
ID=39767571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0917224A BRPI0917224A2 (pt) | 2008-08-05 | 2009-08-04 | formas cristalinas de um derivado de piridina |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8093242B2 (enExample) |
| EP (1) | EP2321324A1 (enExample) |
| JP (1) | JP2011529942A (enExample) |
| KR (1) | KR20110052686A (enExample) |
| CN (1) | CN102171219A (enExample) |
| AU (1) | AU2009279135B2 (enExample) |
| BR (1) | BRPI0917224A2 (enExample) |
| CA (1) | CA2733235A1 (enExample) |
| EA (1) | EA201170300A1 (enExample) |
| GB (1) | GB0814340D0 (enExample) |
| IL (1) | IL210777A0 (enExample) |
| MX (1) | MX2011001414A (enExample) |
| WO (1) | WO2010015626A1 (enExample) |
| ZA (1) | ZA201100426B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2772168C (en) | 2009-08-27 | 2019-01-08 | Glaxosmithkline Llc | Anhydrate forms of a pyridine derivative |
| CN114272242A (zh) * | 2015-05-18 | 2022-04-05 | 康堤医疗有限公司 | 用于治疗性激素依赖性疾病的双重nk-1/nk-3受体拮抗剂 |
| CA3092238A1 (en) | 2018-03-14 | 2019-09-19 | KaNDy Therapeutics Limited | Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists |
| WO2021094247A1 (en) | 2019-11-15 | 2021-05-20 | KaNDy Therapeutics Limited | New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814 |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
| WO2025242585A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69728883T2 (de) | 1996-07-17 | 2005-04-07 | Merck & Co., Inc. | Änderung des zirkadischen rhythmus mit nicht-peptidischen neurokinin-1 rezeptor antagonisten |
| DK1035115T3 (da) | 1999-02-24 | 2005-01-24 | Hoffmann La Roche | 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister |
| WO2001030348A1 (en) | 1999-10-25 | 2001-05-03 | Janssen Pharmaceutica N.V. | Use of substance p antagonists for influencing the circadian timing system |
| GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| GB0203022D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| CN1852712B (zh) | 2003-07-03 | 2010-06-09 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗精神分裂症的双重nk1/nk3拮抗剂 |
| JO2722B1 (en) * | 2005-09-09 | 2013-09-15 | سميث كلاين بيتشام كوربوريشن | New vehicles |
-
2008
- 2008-08-05 GB GBGB0814340.6A patent/GB0814340D0/en not_active Ceased
-
2009
- 2009-08-04 KR KR1020117005159A patent/KR20110052686A/ko not_active Withdrawn
- 2009-08-04 CN CN2009801393221A patent/CN102171219A/zh active Pending
- 2009-08-04 CA CA2733235A patent/CA2733235A1/en not_active Abandoned
- 2009-08-04 JP JP2011521561A patent/JP2011529942A/ja not_active Withdrawn
- 2009-08-04 EP EP09781468A patent/EP2321324A1/en not_active Withdrawn
- 2009-08-04 US US13/056,775 patent/US8093242B2/en active Active
- 2009-08-04 AU AU2009279135A patent/AU2009279135B2/en not_active Ceased
- 2009-08-04 BR BRPI0917224A patent/BRPI0917224A2/pt not_active IP Right Cessation
- 2009-08-04 EA EA201170300A patent/EA201170300A1/ru unknown
- 2009-08-04 MX MX2011001414A patent/MX2011001414A/es unknown
- 2009-08-04 WO PCT/EP2009/060089 patent/WO2010015626A1/en not_active Ceased
-
2011
- 2011-01-17 ZA ZA2011/00426A patent/ZA201100426B/en unknown
- 2011-01-20 IL IL210777A patent/IL210777A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009279135A1 (en) | 2010-02-11 |
| EA201170300A1 (ru) | 2011-08-30 |
| CA2733235A1 (en) | 2010-02-11 |
| GB0814340D0 (en) | 2008-09-10 |
| US8093242B2 (en) | 2012-01-10 |
| MX2011001414A (es) | 2011-04-04 |
| JP2011529942A (ja) | 2011-12-15 |
| US20110136798A1 (en) | 2011-06-09 |
| AU2009279135B2 (en) | 2012-09-13 |
| EP2321324A1 (en) | 2011-05-18 |
| ZA201100426B (en) | 2012-03-28 |
| WO2010015626A1 (en) | 2010-02-11 |
| IL210777A0 (en) | 2011-03-31 |
| KR20110052686A (ko) | 2011-05-18 |
| CN102171219A (zh) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2262793T3 (da) | Krystallinske former af nilotinib-hci | |
| EP2404918A4 (en) | pyridine | |
| BRPI0915714A2 (pt) | forma cristalina de posaconazol | |
| DK2300465T3 (da) | Imidazopyridinderivater som hæmmere af receptortyrosinkinaser | |
| BRPI1013246A2 (pt) | derivados de benzofuralina | |
| EP2376493A4 (en) | DIHYDROPYRIMIDOPYRIMIDINDERIVAT | |
| BR112012002828A2 (pt) | derivados de 5-fluorpirimidinona | |
| EP2380877A4 (en) | PYRIDINE-3-CARBONSÄUREAMIDDERIVAT | |
| ECSP12011999A (es) | Derivados benzamida sustituidos | |
| BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
| BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
| EP2336132A4 (en) | MORPHOLINPURINDERIVAT | |
| EP2397480A4 (en) | DIAZEPINEDIONEDERIVATE | |
| BRPI1013844A2 (pt) | derivados de piridina-isoxazol | |
| BR112012003435A2 (pt) | formas anidras de um derivado de píridina | |
| BRPI1014454A2 (pt) | derivados de isoxazol-pirazol | |
| ATE545635T1 (de) | Substituierte n-oxidpyrazinderivate | |
| BRPI0908512A2 (pt) | elemento tubular | |
| BRPI0913234A2 (pt) | derivados de tiazolilpiperidina | |
| BR112012002810A2 (pt) | derivados de n1-acil-5-fluoropirimidinona | |
| BRPI0922652A2 (pt) | Derivados de quinazolinamida | |
| PT2492266E (pt) | Derivado de 5-hidroxipirimidino-4-carboxamida | |
| BRPI1011416A2 (pt) | derivados de antraquinova novos | |
| EP2401281A4 (en) | PYRIMIDINPYRIMIDOINDAZOLDERIVAT | |
| UY3860Q (es) | Reloj |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |